Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CD69 | Q07108 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PYGB | P11216 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | OGA | O60502 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9343587 | 1.00 | ALDH1A1 (0.55) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL12826779 | 1.00 | ALDH1A1 (0.55) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL15908083 | 1.00 | ALDH1A1 (0.55) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL15910016 | 1.00 | ALDH1A1 (0.55) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL6513543 | 1.00 | ALDH1A1 (0.55) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL6036803 | 1.00 | ALDH1A1 (0.55) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL23635309 | 1.00 | ALDH1A1 (0.55) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL7303486 | 1.00 | ALDH1A1 (0.55) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL9008428 | 1.00 | ALDH1A1 (0.55) | ALDH1A1THRBMAPK1CA1CA2 | |
| SCHEMBL21604317 | 0.86 | ALDH1A1 (0.42) | ALDH1A1THRBMAPK1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114886907-A | (E) Application of-6-O-p-coumaroyl paederosidic methyl ester in preparation of medicine for preventing/treating liver injury | 山东中医药大学附属医院 | 2022-08-12 | — | — | CN | disclosed |
| US-20070197471-A1 | Treatment of degenerative cartilage conditions in a mammal with Glycosidasc Inhibitors | OPTIMER PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197471-A1 | Treatment of degenerative cartilage conditions in a mammal with Glycosidasc Inhibitors | OPTIMER PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197471-A1 | Treatment of degenerative cartilage conditions in a mammal with Glycosidasc Inhibitors | MMP1, MMP13, MMP3 | ALDH1A1 830/4885THRB 3448/4885MAPK1 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.